Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. ReNeuron Group plc
  6. Summary
    RENE   GB00BF5G6K95

RENEURON GROUP PLC

(RENE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
01/20/2022 01/21/2022 01/24/2022 01/25/2022 01/26/2022 Date
42(c) 38(c) 34.5(c) 31.75(c) 34.5(c) Last
1 077 118 411 833 652 385 891 020 763 886 Volume
+5.00% -9.52% -9.21% -7.97% +8.66% Change
More quotes
Estimated financial data (e)
Sales 2022 0,23 M 0,30 M 0,30 M
Net income 2022 - - -
Net cash position 2022 11,1 M 14,9 M 14,9 M
P/E ratio 2022 -
Yield 2022 -
Sales 2023 0,38 M 0,50 M 0,50 M
Net income 2023 - - -
Net cash position 2023 1,36 M 1,82 M 1,82 M
P/E ratio 2023 -
Yield 2023 -
Capitalization 19,7 M 26,6 M 26,5 M
EV / Sales 2022 38,2x
EV / Sales 2023 48,9x
Nbr of Employees -
Free-Float 74,3%
More Financials
Company
ReNeuron Group plc is a United Kingdom-based cell-based therapeutics company. The Company develops allogeneic stem cell technology platforms, stem cell derived exosomes and induced pluripotent stem cells. The Company's products are allogeneic. Its CTX stem cell therapy is used for the treatment of patients left disabled by the effects of a stroke. Its human retinal progenitor cells (hRPC) stem cell candidate is used... 
More about the company
Ratings of ReNeuron Group plc
Trading Rating :  -
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about RENEURON GROUP PLC
01/18ReNeuron Down 39% After Out-Licensing Retinitis Pigmentosa Program
MT
01/18ReNeuron Group plc Provides Strategic Update
CI
01/13ReNeuron, Fosun Supplement Stroke Drug Licensing Deal For Potential Technology Transfer
MT
01/13Reneuron Group plc Announces Additional Agreement with Fosun Pharma for CTX
CI
2021RENEURON : Interim Statement 2021
PU
2021Earnings Flash (RENE.L) RENEURON GROUP Reports H1 Revenue GBP58,000
MT
2021Earnings Flash (RENE.L) RENEURON GROUP Posts H1 Loss GBX-9.20
MT
2021ReNeuron Group plc Reports Earnings Results for the Half Year Ended September 30, 2021
CI
2021RENEURON : New CTX-iPSC platform data shows potential in Peripheral Nerve Repair
PU
2021RENEURON : Collaboration agreement with UCL
PU
2021Reneuron Group plc Enters into Collaboration Agreement with University College London
CI
2021RENEURON : First subject treated at Oxford Eye Hospital in Phase 2a RP trial
PU
2021RENEURON : Further changes in the Board of Directors
PU
2021RENEURON : First subject treated at Oxford Eye Hospital
PU
2021ReNeuron Group plc Announces Changes in the Board of Directors
CI
More news
News in other languages on RENEURON GROUP PLC
01/18ReNeuron en baisse de 39 % après l'octroi d'une licence pour son programme sur la rétin..
01/18ReNeuron Group plc présente une mise à jour stratégique
01/13ReNeuron et Fosun concluent un accord de licence pour un médicament contre les accident..
01/13Reneuron Group plc annonce un accord supplémentaire avec Fosun Pharma pour le CTX
2021Earnings Flash (RENE.L) Le groupe RENEURON annonce un chiffre d'affaires de 58 000 GBP ..
More news
Chart RENEURON GROUP PLC
Duration : Period :
ReNeuron Group plc Technical Analysis Chart | RENE | GB00BF5G6K95 | MarketScreener
Technical analysis trends RENEURON GROUP PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 34,50 GBX
Average target price 147,00 GBX
Spread / Average Target 326%
Managers and Directors
Olav Hellebø Chief Executive Officer & Executive Director
Catherine Isted Chief Financial Officer & Executive Director
Iain Gladstone Ross Non-Executive Chairman
Richard L. Beckman Chief Medical Officer
Stefano Pluchino Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
RENEURON GROUP PLC-57.93%24
MODERNA, INC.-39.94%61 847
LONZA GROUP AG-20.30%49 060
IQVIA HOLDINGS INC.-16.27%45 129
SEAGEN INC.-19.08%22 875
ICON PUBLIC LIMITED COMPANY-19.15%20 381